RxSight Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
RxSight has a total shareholder equity of $275.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $305.5M and $30.3M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$233.28m |
| Eşitlik | US$275.21m |
| Toplam yükümlülükler | US$30.29m |
| Toplam varlıklar | US$305.50m |
Son finansal sağlık güncellemeleri
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Recent updates
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12RxSight: First And Only Customizable Intraocular Lens
Aug 26Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: RXST's short term assets ($281.2M) exceed its short term liabilities ($19.6M).
Uzun Vadeli Yükümlülükler: RXST's short term assets ($281.2M) exceed its long term liabilities ($10.7M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: RXST is debt free.
Borcun Azaltılması: RXST had no debt 5 years ago.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: RXST has sufficient cash runway for more than 3 years based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if RXST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.